{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-113379","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2025-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.207589+00:00","generated_at":"2026-05-17T07:34:08.656992+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alkermes' alixorexton meets primary endpoint in phase 2 NT1 study; all doses improve wakefulness","bullets":["Primary endpoint: MWT mean sleep latency improved by 22.2-26.0 min vs placebo -0.6 min (p<0.01 all doses).","ESS score normalized (-6.4 to -8.7 vs placebo -3.1, p<0.01); cataplexy rate reduced (6mg p=0.01).",">40% of 6mg/8mg patients had 100% cataplexy reduction at week 6; improvements in fatigue/cognition.","No serious TEAEs; common mild-moderate events: pollakiuria, insomnia, salivary hypersecretion, blurred vision.","Global phase 3 program for alixorexton in NT1 to begin Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-113379","json":"https://secwatch.observer/filing/0000950170-25-113379.json","markdown":"https://secwatch.observer/filing/0000950170-25-113379.md","text":"https://secwatch.observer/filing/0000950170-25-113379.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017025113379/0000950170-25-113379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017025113379/alks-20250908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:34:08.656992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}